Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Others

Bioregenx (BRGX) Acquisitions (2024)

Bioregenx has reported Acquisitions over the past 1 years, most recently at $1445.0 for Q1 2024.

For Q1 2024, Acquisitions changed N/A year-over-year to $1445.0; the TTM value through Dec 2024 reached $1445.0, changed N/A, while the annual FY2024 figure was $1445.0, N/A changed from the prior year.
Acquisitions for Q1 2024 was $1445.0 at Bioregenx.
Over five years, Acquisitions peaked at $1445.0 in Q1 2024 and troughed at $1445.0 in Q1 2024.